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DIFFERENTIAL EXPRESSION OF HUMAN BETA DEFENSIN- 2 AND -3 IN
GASTRIC MUCOSA OF HELICOBACTER PYLORI-INFECTED INDIVIDUALS
B. Bauer,* T. Wex, D. Kuester, T. Meyer* and P. Malfertheiner
*Max Planck Institute for Infection Biology, Berlin, Germany; Otto-von-Guericke
University Magdeburg, Magdeburg, Germany
Background: Antimicrobial peptides are keyplayers of initial innate immune
responses to human pathogens. Two major representatives, the human beta de-
fensin 2 and 3 (hBD2, hBD3) are both known to be induced by Helicobacter pylori.
Previously, it was demonstrated in vitro that H. pylori actively abrogates hBD3
expression during prolonged infections. Here we comprehensively assessed hBD2
and hBD3 expression ex vivo in the gastric mucosa of healthy individuals.
Materials and Methods: Twenty volunteers (H. pylori positive and H. pylori
negative: n = 10) were enrolled. H. pylori positive subjects underwent eradication
therapy and repeated the protocol. Expression of both defensins were assessed by
quantitative RT-PCR and ELISA, and correlated with histopathological degree of
gastritis.
Results: hBD2 and hBD3 were found to be ubiquitously expressed in all three
groups. In general, hBD2 levels were elevated in relation to H. pylori infection (up
to 40-fold). This upregulation correlated with degree of gastritis in corpus and
antrum. In contrast, hBD3 mRNA amounts were significantly decreased, while
corresponding protein levels remained unchanged. Eradication therapy led to
normalization of mucosal hBD2 expression, while hBD3 expression demonstrated
high interindividual variations among individuals.
Conclusions: Both defensins are ubiquitously but differentially expressed in
gastric mucosa in relation to H. pylori infection. Ex vivo data support previous in
vitro findings that H. pylori infection is associated with reduced hBD3 expression
in chronic active gastritis.
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BLOOD AND LYMPHATIC MICROVESSELS DENSITY IN GASTRIC MUCOSA
OF DYSPEPTIC PATIENTS
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Introduction: Published data on the role of H. pylori in angiogenesis are con-
tradictory, while its role in lymphangiogenesis has not been investigated.
Aims: To investigate the density of lymphatic and blood vessels, together with H.
pylori infection, in biopsies of gastric body and antrum of dyspeptic patients.
Methods: Biopsies from patients subjected to gastroscopy according to clinical
criteria were studied by immunohistochemistry. Exclusion criteria were: previous
eradication therapy, ulcer disease, regular non-steroidal anti-inflammatory use,
and proton pump inhibitor or antibiotic treatment 15 and 30 days prior to
recruitment respectively. Microvessel density was determined with CD34 and
D2.40 monoclonal antibodies (DAKO, Glostrup, Denmark), which are markers of
blood and lymphatic vasculature respectively. Quantification was performed by
direct counting of microvessels in four fields at 40· magnification. H. pylori
infection was assessed by 13C-urea breath test and/or histopathological diagnosis.
Results: Twenty-three biopsies (13 antral) from 13 patients were studied. Their
median age was 62 years, 46% males, 73% gastritis and/or atrophy and 24% H.
pylori positive. Higher blood microvessels densitiy was associated to H. pylori
infection (p = .03) (Table 1). Microvessels count was slightly elevated, without
statistical signification, among biopsies with histological diagnosis of gastritis.
Further associations with inflammatory activity or location were not found.
Lymphangiogenesis was not related with any of the studied variables.
Conclusions: (1) H. pylori infection was associated with increased gastric
angiogenesis (2) Lymphangiogenesis was not related with the studied clinico-
pathological features.
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APPROACH AGAINST HELICOBACTER PYLORI INFECTION?
A. M. Santos,* M. Oleastro, T. Lopes,* T. Pereira, E. Seixas,§ P. Chaves,
J. Machado§ and A. S. Guerreiro*
*CEDOC/Faculdade de Cieˆncias Me´dicas, Univ. Nova de Lisboa, Lisboa, Portugal;
Instituto nacional de Sau´de Dr. Ricardo Jorge, Lisboa, Portugal; Instituto Portugueˆs
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Accumulated evidence in humans and animals shows that H. pylori up-regulate
the expression of cyclooxygenase (COX)-2 both at mRNA and protein levels
which might be the one of the mechanisms leading to several gastric diseases.
Aim: To study the expression of COX-2 on mice gastric mucosa during long-term
treatment with two nutraceuticals: curcumin and synbiotic 2000 on H. pylori
experimental chronic infection.
Materials and Methods: We infected 45 C57BL/6 mice with SS1 – H. pylori
strain. After infection confirmation by 13C-urea breath test mice where then
treated with either PBS, curcumin (10 mg/mouse) or Synbiotic 2000 (50 mg/
mouse), three times per week. Five mice from each treatment group were
euthanized at week 6, 18 and 27. Gastric samples were removed for COX-2
immunohistochemistry analysis.
Results: All the 45 mice were Hp positive by 13C-urea breath test and immu-
nohistochemistry. In the PBS group the production of COX-2 was significantly
up-regulated at week 6 (area of positive immunostaining 393–544 · 103 pixels),
18 (area of positive immunostaining 242–614 · 103 pixels) and 27 week (area of
positive immunostaining 129–175 · 103 pixels). The treatment with either
curcumin or synbiotic significantly decreased the expression of COX-2 at all time
points.
Conclusions: These results suggest the therapeutic usefulness of both nutra-
ceuticals on COX-2 inhibition during chronic experimental mice H. pylori infec-
tion. The supplementation of diet in humans with curcumin or Synbiotic 2000
may be a novel therapeutic approach against gastric inflammation induced by Hp
infection.
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PRODUCTION OF ANTI-H. PYLORI IMMUNOGLOBULIN Y (IGY) IN THE
CHICKEN EGG YOLK
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Introduction: Immunizing chickens with certain antigens and collecting the
related antibodies have been proposed as a useful method for production of edible
immunoglobulins (Igs). Oral IgY could have applications in the control of gastric
infections such as those caused by Escherichia coli and Salmonella enterica. In this
study immunization of chicken and production of anti-H. pylori IgY in egg yolk
was studied
Methods: A suspension of one heat-killed and PCR-confirmed H. pylori isolate
mixed with freund’s adjuvant was intramuscularly injected to two 5 months-old
chickens, once a week for three consecutive weeks. Ten days after the last
immunization, eggs were collected and total antibody was purified from egg yolk.
The presence of anti-H. pylori IgY was assessed using dot blotting method on
Polyvinylidene fluoride membrane. PCR-confirmed E. coli and Salmonella entrica
were used to eliminate the possibility of cross-reaction.
Results: Specific binding of extracted antibodies to H. pylori-specific antigens was
observed as colored spots on the membrane, indicating the presence of anti-H.
pylori ploycolonal antibodies in the chicken eggs. Colorimetric reaction of anti-
bodies with E. coli and S. entrica-specific antigens were not observed.
Discussion: Immunization of chickens for the production of antibodies has
several advantages such as no need for blood sampling from animals and pro-
duction of a large amount of antibodies in egg yolk. Furthermore, egg yolk
containing anti-H. pylori antibody administered orally could provide a novel and
effective approach to prevent H. pylori infection.
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